Actively Recruiting
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Led by Opna Bio LLC · Updated on 2026-04-13
130
Participants Needed
11
Research Sites
96 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.
CONDITIONS
Official Title
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of multiple myeloma
- Relapsed or refractory to 3 or more prior treatments including immunomodulatory agents, proteosome inhibitors, and anti-CD38 antibody
- Not a candidate for or intolerant to established therapies known to provide clinical benefit
- Adequate blood, kidney, liver, and heart function
You will not qualify if you...
- Diagnosis of monoclonal gammopathy of undetermined significance, smoldering myeloma, Waldenstr48's macroglobulinemia, or IgM myeloma
- Active plasma cell leukemia
- POEMS syndrome
- History of Stevens Johnson syndrome
- Localized radiation therapy within 2 weeks before first dose
- Autologous stem cell or bone marrow transplant within 90 days before first dose
- Allogeneic stem cell or solid organ transplant within 12 months before first dose
- Receiving immunosuppressive medication for active graft versus host disease
- Chemotherapy, targeted cancer therapy, or radiation therapy within 2 weeks before first dose
- Use of high-dose corticosteroids except for chronic steroids for non-myeloma disorders
- Multiple myeloma involvement in the central nervous system
- Active second cancer except treated basal cell carcinoma, squamous cell skin cancer, in situ cervical cancer, or certain low-risk prostate cancers
- Systemic infection requiring intravenous treatment
- Poorly controlled Type 2 diabetes
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 11 locations
1
Banner MD Anderson
Gilbert, Arizona, United States, 85234
Actively Recruiting
2
Stanford Cancer Institute
Stanford, California, United States, 94305
Actively Recruiting
3
Emory Winchip Cancer Center
Atlanta, Georgia, United States, 30322
Actively Recruiting
4
University of Kansas Clinical Research Center
Westwood, Kansas, United States, 66205
Actively Recruiting
5
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Actively Recruiting
6
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
Actively Recruiting
7
START Midwest
Grand Rapids, Michigan, United States, 49546
Actively Recruiting
8
University of Rochester Medical Center
Rochester, New York, United States, 14642
Actively Recruiting
9
University of North Carolina Hospitals at Hillsborough
Chapel Hill, North Carolina, United States, 27599
Actively Recruiting
10
Huntsman Cancer Center Institute University of Utah
Salt Lake City, Utah, United States, 84112
Actively Recruiting
11
Fred Hutchinson Cancer Center
Seattle, Washington, United States, 98109
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here